SCHEMBL3984490

SCHEMBL3984490

CC1(C(N)=O)CC(c2ccccc2)=NO1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.51
CA2 P00918 4/20 0.51
ITGB1 P05556 4/20 0.47
ITGA4 P13612 4/20 0.47
F2 P00734 2/20 0.41
F10 P00742 2/20 0.41
PRSS1 P07477 2/20 0.41
NLRP3 Q96P20 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
RECQL P46063 2/20 0.40
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3903122 0.87 CA1 (0.53) CA1CA2ITGB1ITGA4NLRP3
SCHEMBL3984036 0.86 CA1 (0.44) CA1CA2ITGB1ITGA4F2
SCHEMBL3983893 0.85 CA1 (0.51) CA1CA2ITGB1ITGA4F10
SCHEMBL3984266 0.82 APAF1 (0.46) CA1CA2ITGB1ITGA4KDM4E
SCHEMBL3901277 0.82 ITGB1 (0.54) CA1CA2ITGB1ITGA4F2
SCHEMBL30553810 0.79 CA1 (0.54) CA1CA2ITGB1ITGA4F2
SCHEMBL25401575 0.79 ITGB1 (0.48) CA1CA2ITGB1ITGA4NLRP3
SCHEMBL3984264 0.78 F10 (0.39) CA1CA2ITGB1ITGA4F2
SCHEMBL3984044 0.78 CA1 (0.41) CA1CA2ITGB1ITGA4F2
SCHEMBL3981730 0.76 CA1 (0.37) CA1CA2ITGB1ITGA4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893572-B1 FACTOR XA INHIBITORS MILLENNIUM PHARM INC (US) 2016-12-14 EP claimed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 US claimed
EP-1893572-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-05 EP claimed
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-11 US claimed
WO-2006002099-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
EP-1893572-B1 FACTOR XA INHIBITORS MILLENNIUM PHARM INC (US) 2016-12-14 EP disclosed
US-8377974-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-02-19 US disclosed
US-20120178733-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2012-07-12 US disclosed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 US disclosed
US-7521470-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
EP-1893572-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-05 EP disclosed
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-11 US disclosed
WO-2006002099-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
CN-1046274-C isoxazoline compounds as anti-inflammatory agents PFIZER (US) 1999-11-10 CN disclosed
CN-1143363-A Isoxazoline compounds as inhibitors of TNF release PFIZER (US) 1997-02-19 CN disclosed
CN-1136314-A Isoxazoline compounds as antiinflammatory agents PFIZER (US) 1996-11-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor TFPI, TFPI2, F12 CA1 412/4885CA2 348/4885ITGB1 1666/4885
US-20090298806-A1 FACTOR XA INHIBITORS TFPI, F12, F11 CA1 246/4885CA2 698/4885ITGB1 1205/4885
US-20120178733-A1 FACTOR XA INHIBITORS TFPI, F12, F11 CA1 246/4885CA2 698/4885ITGB1 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.